drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
An antibody-drug conjugate composed of a humanized anti-HER2 monoclonal antibody (disitamab) linked via a cleavable linker to the microtubule-disrupting payload monomethyl auristatin E (MMAE). After binding HER2 on tumor cells, the ADC is internalized and MMAE is released to inhibit tubulin polymerization, causing G2/M arrest and apoptosis; additional effects may include ADCC and a bystander effect.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
disitamab vedotin
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti-HER2 monoclonal antibody (disitamab) delivers the microtubule toxin MMAE via a cleavable linker. After binding HER2, the ADC is internalized and MMAE is released in lysosomes to inhibit tubulin polymerization, causing G2/M arrest and apoptosis; may also induce Fc-mediated ADCC and a membrane-permeable bystander effect.
drug_name
Disitamab vedotin (RC48-ADC)
nct_id_drug_ref
NCT05831878